Harvard Bioscience targets $22.5M-$24.5M Q4 revenue as backlog reaches two-year high, expanding product rollouts and distribution
Source: SeekingAlpha
2025-11-07 02:16:42 ET
More on Harvard Bioscience
- Harvard Bioscience, Inc. (HBIO) Q3 2025 Earnings Call Transcript
- Harvard Bioscience, Inc. (HBIO) Q2 2025 Earnings Call Transcript
- Harvard Bioscience, Inc. 2025 Q2 - Results - Earnings Call Presentation
- Harvard Bioscience outlines $19M–$21M Q3 revenue target as debt refinancing advances and product adoption accelerates
- Harvard Bioscience beats top-line and bottom-line estimates; initiates Q3 outlook
Read the full article on Seeking Alpha
For further details see:
Harvard Bioscience targets $22.5M–$24.5M Q4 revenue as backlog reaches two-year high, expanding product rollouts and distribution
Harvard Bioscience Inc.
NASDAQ: HBIO
HBIO Trading
-6.26% G/L:
$0.5523 Last:
116,559 Volume:
$0.57 Open:
HBIO Latest News
February 26, 2026 07:30:00 am
Harvard Bioscience Schedules Fourth Quarter 2025 Earnings Conference Call for March 12, 2026 at 8:00 AM ET
HBIO Stock Data
$28,178,005
35,641,756
0.25%
23
N/A
Biotechnology & Life Sciences
Healthcare
US
Holliston
